Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Oncolys BioPharma, Inc. ( (JP:4588) ).
Oncolys BioPharma recently presented promising results from a Phase I clinical trial for Telomelysin (OBP-301) combined with chemoradiation therapy at the ASCO GI 2025 symposium. The trial showcased a 100% clinical complete response rate in 13 patients, indicating significant potential for OBP-301 as a viable treatment option for advanced esophageal cancer, thus strengthening Oncolys’ strategic positioning in this market.
More about Oncolys BioPharma, Inc.
Oncolys BioPharma Inc. operates in the biopharmaceutical industry, focusing on developing oncolytic adenoviral immunotherapies. Their primary product, Telomelysin (OBP-301), targets advanced cancers, particularly esophageal and gastro-esophageal cancers, aiming to provide treatment options for patients ineligible for surgery.
YTD Price Performance: 4.63%
Average Trading Volume: 1,098,855
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen13.51B
See more insights into 4588 stock on TipRanks’ Stock Analysis page.